Trevi Therapeutics, Inc.TRVINASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+4.5%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+4.5%/yr
Quarterly compound
Percentile
P100
Near historical high
vs 3Y Ago
1.1x
Modest growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 29.86% |
| Q3 2025 | -7.71% |
| Q2 2025 | 25.05% |
| Q1 2025 | -41.12% |
| Q4 2024 | 0.06% |
| Q3 2024 | -10.05% |
| Q2 2024 | 17.04% |
| Q1 2024 | -64.60% |
| Q4 2023 | 12.64% |
| Q3 2023 | 26.29% |
| Q2 2023 | -20.47% |
| Q1 2023 | -29.47% |
| Q4 2022 | 26.18% |
| Q3 2022 | -38.86% |
| Q2 2022 | 12.92% |
| Q1 2022 | -13.85% |
| Q4 2021 | 13.98% |
| Q3 2021 | 8.32% |
| Q2 2021 | -4.22% |
| Q1 2021 | 15.08% |
| Q4 2020 | -28.09% |
| Q3 2020 | 17.41% |
| Q2 2020 | -80.53% |
| Q1 2020 | 24.65% |
| Q4 2019 | 19.81% |
| Q3 2019 | -52.82% |
| Q2 2019 | -23.56% |
| Q1 2019 | 13.48% |
| Q4 2018 | -18.56% |
| Q3 2018 | 28.82% |
| Q2 2018 | -41.88% |
| Q1 2018 | -139420.11% |
| Q4 2017 | 0.00% |